Avalo Therapeutics Inc (AVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $448.71M
Last updated: Nov 17, 2026 at 11:04 AM ET
Avalo Therapeutics Inc (AVTX) Earnings: Report Dates and Results
Avalo Therapeutics (AVTX) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Avalo Therapeutics reported EPS of -$0.34, above the -$0.63 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AVTX has an expected report date of Mar 22, 2027.
Earnings History
Of the 38 quarters below that had an estimate, AVTX beat 21 and missed 17. The widest gap in the table came in the quarter ended Sep 30, 2017, when EPS landed 500.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.34 | -$0.63 | -$0.66 - -$0.45 | +46.03% | Beat | N/A | 8 | N/A | Nov 5, 2026 | N/A |
| Jun 30, 2026 | -$0.83 | -$0.66 | -$0.94 - -$0.46 | -25.76% | Miss | N/A | 10 | 0 up, 1 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$0.98 | -$1.03 | -$1.29 - -$0.84 | +4.85% | Beat | N/A | 5 | 1 up, 0 down | May 13, 2026 | N/A |
| Dec 31, 2025 | -$0.37 | -$1.50 | -$2.17 - -$0.94 | +75.25% | Beat | N/A | 6 | 1 up, 0 down | Mar 23, 2026 | $59000 |
| Sep 30, 2025 | -$2.19 | -$1.64 | -$1.85 - -$1.25 | -33.54% | Miss | -323.5% | 4 | 0 up, 0 down | Nov 6, 2025 | N/A |
| Jun 30, 2025 | -$1.92 | -$1.43 | -$2.02 - -$1.20 | -34.27% | Miss | -145.6% | 3 | 0 up, 0 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$1.25 | -$1.60 | -$2.02 - -$1.19 | +21.88% | Beat | N/A | 2 | 0 up, 0 down | Apr 4, 2025 | N/A |
| Dec 31, 2024 | -$2.74 | $1.67 | -$1.90 - $5.23 | -264.56% | Miss | N/A | 2 | 0 up, 0 down | Mar 27, 2025 | $192000 |
| Sep 30, 2024 | $0.98 | -$1.19 | -$1.45 - -$0.93 | +182.35% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2024 | $249000 |
| Jun 30, 2024 | $4.21 | -$6.70 | -$6.70 - -$6.70 | +162.84% | Beat | N/A | 1 | 0 up, 0 down | Jul 11, 2024 | N/A |
| Mar 31, 2024 | -$141.00 | -$1.18 | -$1.18 - -$1.18 | N/A | N/A | N/A | 1 | 1 up, 0 down | May 13, 2024 | N/A |
| Dec 31, 2023 | -$116.21 | -$4.80 | -$4.80 - -$4.80 | N/A | N/A | N/A | 1 | 0 up, 0 down | Mar 28, 2024 | $570000 |
| Sep 30, 2023 | -$26.40 | -$264.00 | N/A | +90.00% | Beat | -132.4% | 1 | 0 up, 0 down | Nov 9, 2023 | $236000 |
| Jun 30, 2023 | -$141.60 | -$168.00 | -$214.29 - -$166.67 | +15.71% | Beat | N/A | 2 | 0 up, 0 down | Aug 3, 2023 | $643000 |
| Mar 31, 2023 | -$0.85 | -$0.97 | -$0.97 - -$0.97 | +12.37% | Beat | N/A | 1 | 0 up, 0 down | May 4, 2023 | $475000 |
| Dec 31, 2022 | -$249.60 | -$156.00 | -$269.05 - -$123.81 | -60.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 29, 2023 | $896000 |
| Sep 30, 2022 | $81.60 | -$315.20 | N/A | +125.89% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2022 | $14.95M |
| Jun 30, 2022 | -$331.20 | -$424.80 | N/A | +22.03% | Beat | N/A | 3 | 0 up, 0 down | Aug 4, 2022 | $1.03M |
| Mar 31, 2022 | -$2.40 | -$1.60 | -$1.80 - -$1.44 | -50.00% | Miss | N/A | 2 | 0 up, 0 down | May 5, 2022 | $1.17M |
| Dec 31, 2021 | -$460.80 | -$439.20 | -$514.49 - -$371.58 | -4.92% | Miss | N/A | 5 | 0 up, 0 down | Mar 2, 2022 | $220000 |
| Sep 30, 2021 | -$489.60 | -$518.40 | -$600.24 - -$428.74 | +5.56% | Beat | N/A | 5 | N/A | Nov 9, 2021 | $1.35M |
| Jun 30, 2021 | -$518.40 | -$508.80 | N/A | -1.89% | Miss | N/A | N/A | N/A | Aug 2, 2021 | $3.35M |
| Mar 31, 2021 | -$3.84 | -$2.32 | N/A | -65.52% | Miss | N/A | N/A | N/A | May 13, 2021 | $473000 |
| Dec 31, 2020 | -$489.60 | -$432.00 | N/A | -13.33% | Miss | -136100.0% | N/A | N/A | Mar 8, 2021 | $1.50M |
| Sep 30, 2020 | -$460.80 | -$273.60 | N/A | -68.42% | Miss | N/A | N/A | N/A | Nov 9, 2020 | $1.11M |
| Jun 30, 2020 | -$472.89 | -$302.40 | N/A | -56.38% | Miss | N/A | N/A | N/A | Aug 6, 2020 | $1.34M |
| Mar 31, 2020 | -$247.39 | -$355.20 | N/A | +30.35% | Beat | N/A | N/A | N/A | May 7, 2020 | $2.75M |
| Dec 31, 2019 | $0.36 | $0.84 | N/A | -57.14% | Miss | N/A | N/A | N/A | Mar 11, 2020 | $557177 |
| Sep 30, 2019 | -$213.23 | -$388.80 | N/A | +45.16% | Beat | N/A | N/A | N/A | Nov 14, 2019 | $2.20M |
| Jun 30, 2019 | -$292.61 | -$470.40 | N/A | +37.80% | Beat | N/A | N/A | N/A | Aug 8, 2019 | $1.39M |
| Mar 31, 2019 | -$362.88 | -$470.40 | N/A | +22.86% | Beat | N/A | N/A | N/A | May 9, 2019 | $2.60M |
| Dec 31, 2018 | -$2.16 | -$0.60 | N/A | -260.00% | Miss | N/A | N/A | N/A | Mar 18, 2019 | $7.29M |
| Sep 30, 2018 | -$2,044.78 | -$345.60 | N/A | -491.66% | Miss | -236.5% | N/A | N/A | Nov 13, 2018 | $4.07M |
| Jun 30, 2018 | -$547.20 | -$288.00 | N/A | -90.00% | Miss | N/A | N/A | N/A | Aug 9, 2018 | $4.79M |
| Mar 31, 2018 | -$316.80 | -$662.39 | N/A | +52.17% | Beat | N/A | N/A | N/A | Apr 2, 2018 | $4.48M |
| Sep 30, 2017 | $1,497.59 | -$374.40 | N/A | +500.00% | Beat | N/A | N/A | N/A | Nov 6, 2017 | $25.04M |
| Jun 30, 2017 | -$403.20 | -$633.60 | N/A | +36.36% | Beat | N/A | N/A | N/A | Aug 14, 2017 | $157800 |
| Mar 31, 2017 | -$2.28 | -$4.44 | N/A | +48.65% | Beat | N/A | N/A | N/A | May 9, 2017 | $384206 |
| Dec 31, 2016 | -$549.85 | -$1,785.59 | N/A | +69.21% | Beat | N/A | N/A | N/A | Mar 14, 2017 | $181002 |
| Sep 30, 2016 | -$1,995.77 | -$1,411.19 | N/A | -41.42% | Miss | N/A | N/A | N/A | Nov 8, 2016 | $321497 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.73, after -$138.55 the year before. It was -$6.44 for the year ended Dec 31, 2015, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.73 | N/A |
| Dec 31, 2024 | -$138.55 | N/A |
| Dec 31, 2023 | -$285.06 | N/A |
| Dec 31, 2022 | -$501.60 | N/A |
| Dec 31, 2021 | -$1,472.64 | N/A |
| Dec 31, 2020 | -$1,670.68 | N/A |
| Dec 31, 2019 | -$868.36 | N/A |
| Dec 31, 2018 | -$1,818.83 | N/A |
| Dec 31, 2016 | -$5,445.18 | N/A |
| Dec 31, 2015 | -$6.44 | N/A |
Frequently Asked Questions About AVTX
When is Avalo Therapeutics's next earnings date?
Avalo Therapeutics's next earnings report is expected for Mar 22, 2027.
Did AVTX beat earnings estimates last quarter?
Yes. Avalo Therapeutics reported EPS of -$0.34 for the quarter ended Sep 30, 2026, above the -$0.63 estimate, a 46.03% surprise.
What EPS do analysts expect from AVTX next quarter?
The consensus EPS estimate for Avalo Therapeutics for the quarter ending Dec 31, 2026 is -$0.52 from 14 analysts, with estimates from -$0.69 to -$0.40.
How often does AVTX beat earnings estimates?
Avalo Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -26.26%.
AVTX pages: Overview, Earnings, Forecast, Financials, Competitors